Affimed (NASDAQ:AFMD) will release its earnings data before the market opens on Tuesday, March 20th. Analysts expect Affimed to post earnings of ($0.19) per share for the quarter.
Affimed (NASDAQ:AFMD) traded up $0.02 during mid-day trading on Wednesday, hitting $2.22. 253,921 shares of the company’s stock were exchanged, compared to its average volume of 912,506. Affimed has a one year low of $1.15 and a one year high of $2.85. The company has a market cap of $126.39, a P/E ratio of -2.82 and a beta of 2.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.43 and a quick ratio of 6.39.
Separately, Oppenheimer restated a “hold” rating on shares of Affimed in a research report on Friday, November 24th.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.